CD19 and B-cell non-Hodgkin lymphoma: In the xenogeneic B-cell lymphoma model, multiple injections of UCB Tregs were administered 3 days after CD19 CAR T cell injection, and no detrimental effect of add-on Tregs was noted on the circulating CD8<sup>+</sup> T effector cells.